U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT06891833) titled 'A Study of BL-M07D1 + Pertuzumab With or Without Taxane Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer' on March 18.

Brief Summary: This trial is a registered phase III, randomized, open and multicenter study to evaluate the efficacy and safety of BL-M07D1 + Pertuzumab in combination with or without taxane regimen in the neoadjuvant treatment of HER2-positive breast cancer. The study is divided into a single-arm study phase (Phase II) and a randomized controlled study phase (Phase III).

Study Start Date: April, 2025

Study Type: INTERVENTIONAL

Condition: HER2-positive Breast Can...